AAAAAA

   
Results: 1-25 | 26-32
Results: 1-25/32
PHASE-I TRIAL OF SEQUENTIAL HIGH-DOSE CHEMOTHERAPY WITH ESCALATING DOSE PACLITAXEL, MELPHALAN, AND CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN WITH PERIPHERAL-BLOOD PROGENITOR SUPPORT IN WOMEN WITH RESPONDING METASTATIC BREAST-CANCER
Authors: VAHDAT LT PAPADOPOULOS K BALMACEDA C MCGOVERN T DUNLEAVY J KAUFMAN E FUNG B GARRETT T SAVAGE D TIERSTEN A AYELLO J BAGIELLA E HEITJAN D ANTMAN K HESDORFFER C
Citation: Lt. Vahdat et al., PHASE-I TRIAL OF SEQUENTIAL HIGH-DOSE CHEMOTHERAPY WITH ESCALATING DOSE PACLITAXEL, MELPHALAN, AND CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN WITH PERIPHERAL-BLOOD PROGENITOR SUPPORT IN WOMEN WITH RESPONDING METASTATIC BREAST-CANCER, Clinical cancer research, 4(7), 1998, pp. 1689-1695
SEQUENCE-ANALYSIS OF BRCA1 AND BRCA2 - CORRELATION OF MUTATIONS WITH FAMILY HISTORY AND OVARIAN-CANCER RISK
Authors: FRANK TS MANLEY SA OLOPADE OI CUMMINGS S GARBER JE BERNHARDT B ANTMAN K RUSSO D WOOD ME MULLINEAU L ISAACS C PESHKIN B BUYS S VENNE V ROWLEY PT LOADER S OFFIT K ROBSON M HAMPEL H BRENER D WINER EP CLARK S WEBER B STRONG LC RIEGER P MCCLURE M WARD BE SHATTUCKEIDENS D OLIPHANT A SKOLNICK MH THOMAS A
Citation: Ts. Frank et al., SEQUENCE-ANALYSIS OF BRCA1 AND BRCA2 - CORRELATION OF MUTATIONS WITH FAMILY HISTORY AND OVARIAN-CANCER RISK, Journal of clinical oncology, 16(7), 1998, pp. 2417-2425
HIGH-DOSE MULTIMODALITY THERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT FORSTAGE IIIB BREAST-CARCINOMA
Authors: AYASH LJ ELIAS A IBRAHIM J SCHWARTZ G WHEELER C REICH E LYNCH C WARREN D SHAPIRO C RICHARDSON P HURD D SCHNIPPER L FREI E ANTMAN K
Citation: Lj. Ayash et al., HIGH-DOSE MULTIMODALITY THERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT FORSTAGE IIIB BREAST-CARCINOMA, Journal of clinical oncology, 16(3), 1998, pp. 1000-1007
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL SUPPORT FOR BREAST-CANCER IN NORTH-AMERICA - REPLY
Authors: ANTMAN K
Citation: K. Antman, HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM-CELL SUPPORT FOR BREAST-CANCER IN NORTH-AMERICA - REPLY, Journal of clinical oncology, 16(2), 1998, pp. 801-802
PHASE-I TRIAL OF RETROVIRAL-MEDIATED TRANSFER OF THE HUMAN MDR1 GENE AS MARROW CHEMOPROTECTION IN PATIENTS UNDERGOING HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION
Authors: HESDORFFER C AYELLO J WARD M KAUBISCH A VAHDAT L BALMACEDA C GARRETT T FETELL M REISS R BANK A ANTMAN K
Citation: C. Hesdorffer et al., PHASE-I TRIAL OF RETROVIRAL-MEDIATED TRANSFER OF THE HUMAN MDR1 GENE AS MARROW CHEMOPROTECTION IN PATIENTS UNDERGOING HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL TRANSPLANTATION, Journal of clinical oncology, 16(1), 1998, pp. 165-172
A SOUTHWEST-ONCOLOGY-GROUP AND CANCER AND LEUKEMIA GROUP-B PHASE-II STUDY OF DOXORUBICIN, DACARBAZINE, IFOSFAMIDE, AND MESNA IN ADULTS WITHADVANCED OSTEOSARCOMA, EWINGS-SARCOMA, AND RHABDOMYOSARCOMA
Authors: ANTMAN K CROWLEY J BALCERZAK SP KEMPF RA WEISS RB CLAMON GH BAKER LH
Citation: K. Antman et al., A SOUTHWEST-ONCOLOGY-GROUP AND CANCER AND LEUKEMIA GROUP-B PHASE-II STUDY OF DOXORUBICIN, DACARBAZINE, IFOSFAMIDE, AND MESNA IN ADULTS WITHADVANCED OSTEOSARCOMA, EWINGS-SARCOMA, AND RHABDOMYOSARCOMA, Cancer, 82(7), 1998, pp. 1288-1295
A PHASE-II SOUTHWEST-ONCOLOGY-GROUP STUDY OF CISPLATIN AND CONTINUOUS-INFUSION VINBLASTINE IN THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMA
Authors: KEOHAN ML GREVER MR BALCERZAK SP ANTMAN K
Citation: Ml. Keohan et al., A PHASE-II SOUTHWEST-ONCOLOGY-GROUP STUDY OF CISPLATIN AND CONTINUOUS-INFUSION VINBLASTINE IN THE TREATMENT OF ADVANCED SOFT-TISSUE SARCOMA, Investigational new drugs, 15(3), 1997, pp. 255-256
ADJUVANT CHEMOTHERAPY FOR LOCALIZED RESECTABLE SOFT-TISSUE SARCOMA OFADULTS - METAANALYSIS OF INDIVIDUAL DATA
Authors: TIERNEY JF STEWART LA PARMAR MKB FLETCHER CDM JONES G MOSSERI V PATEL M DEELVIRA MCR SOUHAMI RL SYLVESTER R TURSZ T ALVEGARD TA SIGURDSSON H ANTMAN K BACCHI M BAKER LH BENJAMIN RS BRADY MF BRAMWELL V BUI BN EDMONSON JH LEYVRAZ S OMURA GA ROUESSE J RYAN L VANOOSTEROM AT YANG JC
Citation: Jf. Tierney et al., ADJUVANT CHEMOTHERAPY FOR LOCALIZED RESECTABLE SOFT-TISSUE SARCOMA OFADULTS - METAANALYSIS OF INDIVIDUAL DATA, Lancet, 350(9092), 1997, pp. 1647-1654
FEASIBILITY OF 3 G M2 OF INTRAVENOUS METHOTREXATE (IVMTX) FOR PRIMARYCENTRAL-NERVOUS-SYSTEM LYMPHOMA (PCNSL)/
Authors: SHERMAN W BALMACEDA C NICHOLS G MEARS G ANTMAN K
Citation: W. Sherman et al., FEASIBILITY OF 3 G M2 OF INTRAVENOUS METHOTREXATE (IVMTX) FOR PRIMARYCENTRAL-NERVOUS-SYSTEM LYMPHOMA (PCNSL)/, Neurology, 48(3), 1997, pp. 1002-1002
FEASIBILITY OF HIGH-DOSE CHEMOTHERAPY (HDC) FOLLOWED BY AUTOLOGOUS ORSTEM-CELL SUPPORT FOR RECURRENT PROGRESSIVE OLIGODENDROGLIOMA(O)/
Authors: BALMACEDA C HESDORFFER C PAPPADOUPOLOUS K SIMMONS T VAHDAT L GARRET T ANTMAN K FETELL MR
Citation: C. Balmaceda et al., FEASIBILITY OF HIGH-DOSE CHEMOTHERAPY (HDC) FOLLOWED BY AUTOLOGOUS ORSTEM-CELL SUPPORT FOR RECURRENT PROGRESSIVE OLIGODENDROGLIOMA(O)/, Neurology, 48(3), 1997, pp. 1004-1004
BRCA1 AND BRCA1 SEQUENCE-ANALYSIS OF 335 HIGH-RISK WOMEN
Authors: FRANK TS MANLEY S THOMAS A MCCLURE M WARD BE SHATTUCKEIDENS D OLIPHANT A ANTMAN K BERNHARDT B BUYS S CUMMINGS S EDGE S FARRELL C GARBER J ISAACS C LOADER S OFFIT K OLOPADE F PESHKIN B ROWLEY P RUSSO D STRONG L VENNE V WEBER B WINER E WOOD M WOOD WC SKOLNICK M
Citation: Ts. Frank et al., BRCA1 AND BRCA1 SEQUENCE-ANALYSIS OF 335 HIGH-RISK WOMEN, American journal of human genetics, 61(4), 1997, pp. 351-351
DOUBLE DOSE-INTENSIVE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT FOR METASTATIC BREAST-CANCER - NO IMPROVEMENT IN PROGRESSION-FREE SURVIVAL BY THE SEQUENCE OF HIGH-DOSE MELPHALAN FOLLOWED BY CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN
Authors: AYASH LJ ELIAS A SCHWARTZ G WHEELER C IBRAHIM J TEICHER BA REICH E WARREN D LYNCH C RICHARDSON P SCHNIPPER L FREI E ANTMAN K
Citation: Lj. Ayash et al., DOUBLE DOSE-INTENSIVE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT FOR METASTATIC BREAST-CANCER - NO IMPROVEMENT IN PROGRESSION-FREE SURVIVAL BY THE SEQUENCE OF HIGH-DOSE MELPHALAN FOLLOWED BY CYCLOPHOSPHAMIDE, THIOTEPA, AND CARBOPLATIN, Journal of clinical oncology, 14(11), 1996, pp. 2984-2992
WHEN ARE BONE-MARROW TRANSPLANTS CONSIDERED
Authors: ANTMAN K
Citation: K. Antman, WHEN ARE BONE-MARROW TRANSPLANTS CONSIDERED, Scientific American, 275(3), 1996, pp. 124-125
NCI INTRAMURAL PROGRAM REVIEW COMPLETE - PUBLIC COMMENT SOUGHT ON RECOMMENDATIONS
Authors: BISHOP JM CALABRESI P ANTMAN K BALTIMORE D FOLKMAN J LIVINGSTONE DM MINNA JD PICKETT CB ROSENBERG L STRONG LC VOGELSTEIN B WELLS SA RIMER BK KALT M SONDIK EJ
Citation: Jm. Bishop et al., NCI INTRAMURAL PROGRAM REVIEW COMPLETE - PUBLIC COMMENT SOUGHT ON RECOMMENDATIONS, Journal of the National Cancer Institute, 87(12), 1995, pp. 877-883
PROGNOSTIC FACTORS FOR PROLONGED PROGRESSION-FREE SURVIVAL WITH HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT FOR ADVANCED BREAST-CANCER
Authors: AYASH LJ WHEELER C FAIRCLOUGH D SCHWARTZ G REICH E WARREN D SCHNIPPER L ANTMAN K FREI E ELIAS A
Citation: Lj. Ayash et al., PROGNOSTIC FACTORS FOR PROLONGED PROGRESSION-FREE SURVIVAL WITH HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT FOR ADVANCED BREAST-CANCER, Journal of clinical oncology, 13(8), 1995, pp. 2043-2049
PRESIDENTIAL-ADDRESS - MAY 22, 1995 - 31ST ANNUAL-MEETING OF THE AMERICAN-SOCIETY-OF-CLINICAL-ONCOLOGY
Authors: ANTMAN K
Citation: K. Antman, PRESIDENTIAL-ADDRESS - MAY 22, 1995 - 31ST ANNUAL-MEETING OF THE AMERICAN-SOCIETY-OF-CLINICAL-ONCOLOGY, Journal of clinical oncology, 13(12), 1995, pp. 2981-2989
HIGH-DOSE IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE PHARMACOKINETICS - CORRELATION OF PLASMA DRUG LEVELS WITH RENAL TOXICITY
Authors: WRIGHT JE ELIAS A TRETYAKOV O HOLDEN S ANDERSEN J WHEELER C SCHWARTZ G ANTMAN K ROSOWSKY A FREL E AYASH LJ
Citation: Je. Wright et al., HIGH-DOSE IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE PHARMACOKINETICS - CORRELATION OF PLASMA DRUG LEVELS WITH RENAL TOXICITY, Cancer chemotherapy and pharmacology, 36(4), 1995, pp. 345-351
HIGH-DOSE THERAPY FOR BREAST-CANCER
Authors: VAHDAT L ANTMAN K
Citation: L. Vahdat et K. Antman, HIGH-DOSE THERAPY FOR BREAST-CANCER, Blood reviews, 9(3), 1995, pp. 191-200
THE COLLECTION AND EVALUATION OF PERIPHERAL-BLOOD PROGENITOR CELLS SUFFICIENT FOR REPETITIVE CYCLES OF HIGH-DOSE CHEMOTHERAPY SUPPORT
Authors: BENJAMIN RJ LINSLEY L AXELROD JD CHURCHILL WH SIEFF C SHULMAN LN ELIAS A AYASH L MALACHOWSKI ME UHL L GAYNES L MCCAULEY M THOMPSON L MAZANET R ANTMAN K SCHNIPPER L TEPLER I ANTIN JH WHEELER C
Citation: Rj. Benjamin et al., THE COLLECTION AND EVALUATION OF PERIPHERAL-BLOOD PROGENITOR CELLS SUFFICIENT FOR REPETITIVE CYCLES OF HIGH-DOSE CHEMOTHERAPY SUPPORT, Transfusion, 35(10), 1995, pp. 837-844
CLINICAL PROTOCOL - HUMAN MDR GENE-TRANSFER IN PATIENTS WITH ADVANCEDCANCER
Authors: HESDORFFER C ANTMAN K BANK A FETELL M MEARS G BEGG M
Citation: C. Hesdorffer et al., CLINICAL PROTOCOL - HUMAN MDR GENE-TRANSFER IN PATIENTS WITH ADVANCEDCANCER, Human gene therapy, 5(9), 1994, pp. 1151-1160
DOUBLE DOSE-INTENSIVE CHEMOTHERAPY WITH AUTOLOGOUS MARROW AND PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT FOR METASTATIC BREAST-CANCER - A FEASIBILITY STUDY
Authors: AYASH LJ ELIAS A WHEELER C REICH E SCHWARTZ G MAZANEF R TEPLER I WARREN D LYNCH C GONIN R SCHNIPPER L FREI E ANTMAN K
Citation: Lj. Ayash et al., DOUBLE DOSE-INTENSIVE CHEMOTHERAPY WITH AUTOLOGOUS MARROW AND PERIPHERAL-BLOOD PROGENITOR-CELL SUPPORT FOR METASTATIC BREAST-CANCER - A FEASIBILITY STUDY, Journal of clinical oncology, 12(1), 1994, pp. 37-44
RECOMBINANT-HUMAN-ERYTHROPOIETIN FOR THE TREATMENT OF THE ANEMIA ASSOCIATED WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION
Authors: AYASH LJ ELIAS A HUNT M DEMETRI G WHEELER C TEPLER I SCHWARTZ G MAZANET R REICH E MCCAULEY M ANTMAN K ANDERSON KC
Citation: Lj. Ayash et al., RECOMBINANT-HUMAN-ERYTHROPOIETIN FOR THE TREATMENT OF THE ANEMIA ASSOCIATED WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION, British Journal of Haematology, 87(1), 1994, pp. 153-161
STRATEGIES FOR MOBILIZATION OF PERIPHERAL-BLOOD STEM-CELLS FOR USE INHIGH-DOSE CHEMOTHERAPY
Authors: WEBB IJ AYASH LJ EICKHOFF CE WHEELER C SCHWARTZ G MAZANET R DEMETRI G ANTMAN K SCHNIPPER L FREI E ELIAS A
Citation: Ij. Webb et al., STRATEGIES FOR MOBILIZATION OF PERIPHERAL-BLOOD STEM-CELLS FOR USE INHIGH-DOSE CHEMOTHERAPY, Blood, 84(10), 1994, pp. 10000105-10000105
RANDOMIZED PHASE-II TRIAL OF CISPLATIN WITH MITOMYCIN OR DOXORUBICIN FOR MALIGNANT MESOTHELIOMA BY THE CANCER AND LEUKEMIA GROUP-B
Authors: CHAHINIAN AP ANTMAN K GOUTSOU M CORSON JM SUZUKI Y MODEAS C HERNDON JE AISNER J ELLISON RR LEONE L VOGELZANG NJ GREEN MR
Citation: Ap. Chahinian et al., RANDOMIZED PHASE-II TRIAL OF CISPLATIN WITH MITOMYCIN OR DOXORUBICIN FOR MALIGNANT MESOTHELIOMA BY THE CANCER AND LEUKEMIA GROUP-B, Journal of clinical oncology, 11(8), 1993, pp. 1559-1565
AN INTERGROUP PHASE-III RANDOMIZED STUDY OF DOXORUBICIN AND DACARBAZINE WITH OR WITHOUT IFOSFAMIDE AND MESNA IN ADVANCED SOFT-TISSUE AND BONE SARCOMAS
Authors: ANTMAN K CROWLEY J BALCERZAK SP RIVKIN SE WEISS GR ELIAS A NATALE RB COOPER RM BARLOGIE B TRUMP DL DOROSHOW JH AISNER J PUGH RP WEISS RB COOPER BA CLAMOND GH BAKER LH
Citation: K. Antman et al., AN INTERGROUP PHASE-III RANDOMIZED STUDY OF DOXORUBICIN AND DACARBAZINE WITH OR WITHOUT IFOSFAMIDE AND MESNA IN ADVANCED SOFT-TISSUE AND BONE SARCOMAS, Journal of clinical oncology, 11(7), 1993, pp. 1276-1285
Risultati: 1-25 | 26-32